5 Reasons to Add Sierra Oncology to Your Portfolio
Sierra Oncology, Inc. (NASDAQ: SRRA) is focussed on creating novel targeted therapies that address large unmet needs in rare forms of cancer. The Company’s lead product candidate is momelotinib, a selective and orally bioavailable JAK1, JAK2 and ACVR1/ALK2 inhibitor being developed for the treatment of...
